IQuum Gets FDA Emergency Use OK for H1N1 Molecular Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IQuum, a privately held molecular diagnostics firm, has gained Emergency Use Authorization from the US Food and Drug Administration for its Liat Influenza A/2009 H1N1 Assay.

The nucleic acid test can be performed from sample to result in 26 minutes. According to the firm, the Liat assay can detect and differentiate 2009 H1N1 influenza viral RNA from nasopharyngeal swab samples and has shown 100 percent agreement with an EUA comparator assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.